HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL

被引：0
|
作者：
Lawrance, R. [1 ]
DeRosa, M. [2 ]
Taylor, F. [2 ]
Penrod, J. R. [3 ]
Shaw, J. W. [4 ]
Wang, P. F. [5 ]
机构：
[1] Adelphi Values, Bollington SK10 5JB, Cheshire, England
[2] Adelphi Values, Boston, MA USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[5] BMS, Jamison, PR USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.247
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN123
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [1] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Tu, Haiyan
    Wu, Lin
    Feng, Jifeng
    Zhang, Yiping
    Luft, Alexander Valeriercich
    Zhou, Jianying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Baudelet, Christine
    Li, Zoe
    Chang, Jianhua
    CANCER RESEARCH, 2018, 78 (13)
  • [2] CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Wu, Y.
    Chang, J.
    Zhang, L.
    Tu, H.
    Wu, L.
    Feng, J.
    Lu, S.
    Zhou, C.
    Wang, J.
    Mok, T.
    Taylor, F.
    Mossman, B.
    Penrod, J.
    Lawrance, R.
    Blum, S.
    Wang, P. F.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1048
  • [3] Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Tu, Hai-Yan
    Wu, Lin
    Feng, Jifeng
    Zhang, Yiping
    Luft, Alexander Valerievich
    Zhou, Jianying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Baudelet, Christine
    Cai, Junliang
    Chang, Jianhua
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : 867 - 875
  • [4] Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
    Reck, M.
    Coon, C.
    Taylor, F.
    DeRosa, M.
    Penrod, J. R.
    Dastani, H.
    Orsini, L.
    Gralla, R. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S599 - S600
  • [5] Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
    Reck, M.
    Coon, C.
    Taylor, F.
    Derosa, M.
    Penrod, J. R.
    Dastani, H.
    Orsini, L.
    Gralla, R. J.
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [6] Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
    Chang, Jianhua
    Wu, Yi-Long
    Lu, Shun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Feng, Jifeng
    Wu, Lin
    Tu, Hai-Yan
    Zhang, Yiping
    Luft, Alexander
    Zhou, Jian-ying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Poddubskaya, Elena
    Soo, Ross A.
    Chia, Yee Hong
    Penrod, John R.
    Taylor, Fiona
    Lawrance, Rachael
    Blum, Steven, I
    Sun, Xiaowu
    Juarez-Garcia, Ariadna
    Moreno-Koehler, Alejandro
    Li, Ang
    Li, Amy
    Cheng, Ying
    LUNG CANCER, 2022, 165 : 71 - 81
  • [7] Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
    Felip Font, E.
    Gettinger, S. N.
    Burgio, M. A.
    Antonia, S. J.
    Holgado, E.
    Spigel, D. R.
    Arrieta, O.
    Domine Gomez, M.
    Aren Frontera, O.
    Brahmer, J.
    Chow, L. Q.
    Crino, L.
    Butts, C.
    Coudert, B.
    Horn, L.
    Steins, M.
    Geese, W. J.
    Li, A.
    Healey, D.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Three-Year Follow-Up From checkMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
    Felip, Enriqueta
    Gettinger, Scott
    Burgio, Marco Angelo
    Antonia, Scott J.
    Holgado, Esther
    Spigel, David
    Arrieta, Oscar
    Domine, Manuel
    Aren Frontera, Osvaldo
    Brahmer, Julie
    Chow, Laura Q.
    Crino, Lucio
    Butts, Charles
    Coudert, Bruno
    Horn, Leora
    Steins, Martin
    Geese, William J.
    Li, Ang
    Healey, Diane
    Vokes, Everett E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 142 - 143
  • [9] Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
    Crino, L.
    Horn, L.
    Felip, E.
    Frontera, O. Aren
    Burgio, M.
    Waterhouse, D.
    Blumenschein, G.
    Barlesi, F.
    Garassino, M.
    Holgado, E.
    Antonia, S.
    Spigel, D.
    Gainor, J.
    Gettinger, S.
    Geese, W.
    Li, A.
    Healey, D.
    Ready, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2302
  • [10] Impact of of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study
    Reck, Martin
    Taylor, Fiona
    Penrod, John R.
    DeRosa, Michael
    Morrissey, Laura
    Dastani, Homa
    Orsini, Lucinda
    Gralla, Richard J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 194 - 204
12345